Abstract:Efficient capture and presentation of tumor antigens by antigen-presenting cells (APCs), especially dendritic cells (DCs), are crucial for activating the anti-tumor immunity. However, APCs are immunosuppressed in the tumor microenvironment, which hinders the tumor elimination. To reprogram APCs for inducing strong anti-tumor immunity, we report here a co-delivery immunotherapeutic strategy targeting the phagocytosis checkpoint (signal regulatory protein α, SIRPα) and stimulator of interferon genes (STING) of APCs to jointly enhance their ability of capturing and presenting tumor antigens. In brief, a small interfering RNA targeting SIRPα (siSIRPα) and a STING agonist (cGAMP) were co-delivered into APCs by the encapsulation into poly(ethylene glycol)-b-poly(lactide-co-glycolide)-based polymeric nanoparticles (NPsiSIRPα/cGAMP). siSIRPα-mediated SIRPα silence promoted APCs to actively capture tumor antigens by engulfing tumor cells. The cGAMP-stimulated STING signaling pathway further enhanced the functions of APCs, thereby increased the activation and expansion of CD8+ T cells. Using ovalbumin (OVA)-expressing melanoma as a model, we demonstrated that NPsiSIRPα/cGAMP stimulated the activation of OVA-specific CD8+ T cells and induced holistic anti-tumor immune responses by reversing the immunosuppressive phenotype of APCs. Collectively, this co-delivery strategy synergistically enhanced the functions of APCs and can be extended to the treatment of tumors with poor immunogenicity.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c08329?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c08329</a>.Stability of NPsiSIRPα/cGAMP; percentage of CD11b+CD11c+ BMDCs; concentrations of type I IFNs in vitro; analysis of hemolytic anemia; gating strategies of flow cytometry analysis; subtypes of T cells in tumor and tDLN; and primers for qRT-PCR analysis (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c08329/suppl_file/am1c08329_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Redirecting Immunity Via Covalently Incorporated Immunogenic Sialic Acid on the Tumor Cell Surface.

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Liposome-aided Metabolic Engineering of Tumor Surface Immunogenicity

Tumor Suppression Via Diverting Intracellular Sialylation with Multifunctional Nanoparticles.

Generation of Triacyl Lipopeptide-Modified Glycoproteins by Metabolic Glycoengineering As the Neoantigen to Boost Anti-Tumor Immune Response.

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immune‐Killing

Disrupting the Interplay Between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer.

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immuno‐Killing

A Novel Cancer Immunotherapy Based on the Combination of a Synthetic Carbohydrate-Pulsed Dendritic Cell Vaccine and Glycoengineered Cancer Cells.

Enhancing Antigen Delivery Using Spherical Nucleic Acidsfor Optimal Prostate Cancer Immunotherapy

Take Immune Cells Back on Track: Glycopolymer-Engineered Tumor Cells for Triggering Immune Response

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Engineered Bacteria-Mediated Augmentation of Sialoglycan Degradation Strategy and Immunogenic Chemotherapy to Boost Effective Cancer Therapy

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy

Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy.

Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans

Targeted glycan degradation potentiates the anticancer immune response in vivo

Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System